Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
POXEL logo — company profile

POXEL

Founded 2009 France France 25 employees Post-IPO Equity Total: $103.50M Biotechnology, Health Care +1

General Information

Company Name POXEL
Founded Year 2009
Location France France
Founders / Decision Makers
Team member
Employees 25
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with POXEL. To contact POXEL, visit poxel.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About POXEL

POXEL is a clinical stage biopharmaceutical company with a focus on developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. The company has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. In the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) is in a streamlined Phase 2 trial (DESTINY1). PXL770, a first-in-class direct AMPK activator, has successfully completed a Phase 2a proof-of-concept trial for the treatment of NASH with positive outcomes. Additionally, for the rare inherited metabolic disorder, adrenoleukodystrophy (ALD), the company intends to initiate Phase 2a proof of concept studies with PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN). The company's lead product, TWYMEEG® (Imeglimin), has been approved and launched for the treatment of type 2 diabetes in Japan, and the company expects to receive sales-based payments and royalties from Sumitomo Dainippon Pharma. With a strategic partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South Korea, Taiwan, and nine other Southeast Asian countries, Poxel is poised for further expansion and growth. It is listed on Euronext Paris and is headquartered in Lyon, France, with subsidiaries in Boston, MA, and Tokyo, Japan. In March 2023, the company secured a €3.50MPost-IPO Equity investment from Iris Capital Investment.

Services & Products

Developing innovative treatments for chronic serious diseases with metabolic pathophysiology

Target Customers

Patients suffering from NASH rare metabolic diseases and type 2 diabetes

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity €3.50M 1
Iris Capital Investment
Iris Capital Investment
23 Mar 2023
Post IPO Debt Undisclosed 1
IPF Partners
IPF Partners
08 Aug 2022
Post IPO Equity €6.00M 1
Iris Capital Investment
Iris Capital Investment
08 Aug 2022
Post IPO Equity €26.50M -
18 Jul 2016
Post IPO Equity €20.00M -
24 Jul 2015
Series B $13.50M 3
Bpifrance Andera Partner Kreos Capital
Bpifrance, Andera Partner +1
09 Sep 2014
Series B €13.00M 3
Omnes Capital Andera Partner
Omnes Capital, Andera Partner +1
18 Dec 2012
Series A $21.00M 4
Omnes Capital Andera Partner Crédit Agricole
Omnes Capital, Andera Partner +2
08 Jul 2010

FAQ About POXEL

Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activate...
POXEL was founded in 2009.
POXEL is headquartered in France.
POXEL operates in Biotechnology, Health Care and Pharmaceutical. Its customers include Patients suffering from NASH, rare metabolic diseases and and type 2 diabetes.
POXEL has approximately 25 employees.
POXEL has completed 8 funding rounds, raising a total of $103.50M. The latest funding stage is Post-IPO Equity.
POXEL offers: Developing innovative treatments for chronic serious diseases with metabolic pathophysiology.

We're actively collecting intelligence on POXEL.

Source: BounceWatch company record for POXEL, https://bouncewatch.com/company/poxel, updated 7 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes